• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NewLink receives $8.1M award for Ebola vaccine

NewLink receives $8.1M award for Ebola vaccine

October 2, 2015
CenterWatch Staff

The Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense has awarded a subsidiary of NewLink Genetics an $8.1 million base contract with future options totaling $5.2 million to support various development activities of the investigational rVSV-ZEBOV (Ebola) vaccine candidate. NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck.

The rVSV-ZEBOV (Ebola) vaccine candidate originally was developed by the Public Health Agency of Canada (PHAC) and subsequently was licensed to a subsidiary of NewLink Genetics. In late 2014, Merck, known as MSD outside the U.S. and Canada, licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate the development of the vaccine candidate. Clinical studies of the rVSV-ZEBOV are ongoing.

“The new contract from DTRA is key to the continuing rapid development of this Ebola vaccine candidate,” said Dr. Charles Link, CEO and chief scientific officer of NewLink Genetics. “These funds will support studies of our Ebola vaccine candidate that we hope will demonstrate its safety in large rural populations.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing